Skip to contentA
Agios Pharmaceuticals, Inc.
A
AGIOAgios Pharmaceuticals, Inc. Q2 2016 · 10-Q
Revenue$6.98M$6.98M−47.2% vs Q2 2015 Net Income-$55.95M-$55.95MN/M vs Q2 2015 EPS Diluted-$1.47-$1.47N/M vs Q2 2015 Operating Income-$56,470,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Agios Pharmaceuticals, Inc. · CIK 1439222 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$155,090,000N/M Margins · derivedOperating margin-809.3%−566.2 pt vs Q2 2015
Net margin-801.8%−560.6 pt vs Q2 2015
ended Jun 30, 2016 · filed Aug 8, 2016 · 39 d after period end